BioNTech's BNT116, the first mRNA lung cancer vaccine, has entered Phase 1 clinical trials across seven countries, targeting non-small cell lung cancer (NSCLC).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.